AKTTYVA THERAPEUTICS, INC.

Biotech · Private

AI-assisted drug discovery platform for identifying small molecule therapeutics that repair vascular permeability

Grants
$1.3M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: AI-assisted identification of small molecules for targeted repair of vascular barrier dysfunctions$255,487
Federal grantNational Science Foundation · Phase II · SBIR Phase II: AI-assisted identification of small molecules for targeted repair of vascular barrier dysfunctions$999,878
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1868Evoke Pharma Inc—$6.0M
1869Kiniksa Pharmaceuticals—$5.9M
1870Jennerex, Inc.—$5.4M
1871AKTTYVA THERAPEUTICS, INC.——
1872Oncolix, Inc.—$8.9M
1873COURAGE THERAPEUTICS INC—$4.5M
1874Factor Holdings LLC—$25K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • MK2 Activating Compounds For Use In Treating Vascular Leak And Endothelial Barrier Disordersapplication
  • MK2 Activating Compounds For Use In Treating Vascular Leak And Endothelial Barrier Disordersapplication
  • MK2 Activating Compounds For Use In Treating Respiratory Disordersapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.